Figure 5. MiR-378b is able to target SLC2A1 in glioma cells. (A) The binding site prediction of SLC2A1 and miR-378b in ENCORI database. (B and C) The U251 and U87 cells were treated with miR-378b mimic. (B) The luciferase activity of SLC2A1 was measured by dual luciferase reporter assays. (C) The expression of SLC2A1 was analyzed by qPCR. (D) The expression of SLC2A1 was determined by Western blot analysis in U251 and U87 cells treated ZNF609 siRNA or co-treated with ZNF609 siRNA and miR-378b inhibitor. (E and F) The expression and correlation of ZNF609, miR-378b, and SLC2A1 were analyzed in the clinical glioma samples (n = 38). mean ± SD, **P < 0.01.